New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
Details of the presentation are below.
Title: Low-dose Add-on Fenfluramine in Dravet Syndrome: Effect on Seizure Control, Sleep Quality, and Quality of Life in a Prospective Open-label Study
Date: May 5, 2016
Session Title: Epilepsy - Treatment and outcome 2
About the ZX008 Phase 3 Program
For more information, visit www.zogenix.com.
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | Andrew@lifesciadvisors.com